DHR
Danaher Corporation
stock NYSE

Speaking from the past 5-year plans where solar, battery, transportation, R&D, urban development, etc. which inevitably sent ripples through the global economy in each of these sectors, I'd like to start a discussion on who we see profiting the most from China's 2026-2030 5 year plan.
The previous 5 year plan naturally resulted in many western companies floundering (for instance Germany used to produce solar panels) due to state sponsored Chinese industrial investments undercutting them. On the other hand, we have companies such as solar/battery installers and integrators that profited greatly from the new influx of cheap Chinese panels and batteries. But the previous 5 year plan is not where the long-term play is hiding, and I think the latest will be where we see new winners and losers arise.
The 4 main focus technology sectors in the latest 5 year plan that I see are:
* **"Embodied Intelligence"** - meaning humanoid robots, drones with industrial purpose, and AI with a physical presence
* **Further investment into green tech** - meaning green hydrogen equipment, next-gen solar, and advances in battery storage
* **6G, edge AI computing, optical components** - I see resulting in generally cheaper foundational networking components
* **SynBio and advanced biomanufacturing** - Cheaper bio-manufactured precursor chemicals and raw materials
I think a lot of profit can be made by determining not so much the next "big thing" or "bubble before it becomes a bubble," but instead looking at what the Chinese state is publicly telling us they are going to invest in, heavily, for 5 straight years and *who* will profit from the uptick in supply.
Now personally I believe the Embodied Intelligence space is overbought with the AI hype/bubble.
Green tech I believe already has these winners in place due to the previous 5 year plan and cheaper solar/energy storage. No doubt gains will continue to be made here, and perhaps there is something to consider for cheaper energy.
Cheaper networking components will likely make faster internet more affordable both for companies and consumers, however I don't see revolutionary changes likely in the ISP space.
This to me leaves the BioTech space where I think we will see businesses suddenly able to source significantly cheaper bio-manufactured precursor chemicals and raw materials. I could see western Biotech being undercut on design costs for commodity bio-chemicals by their Chinese subsidized equivalents, reverse engineered microbes being rapidly scaled, or Chinese self-reliance cutting out western hardware. On the other hand where I'm thinking the value might lie is with those best positioned to capitalize on China's building.
To me, there are three distinct buckets of companies poised to make a killing by benefiting from this incoming wave of Chinese biomanufacturing.
* **Precision Hardware & QA Enablers** - China is going to subsidize massive amounts of bioreactors and raw material platforms but that doesn't mean you they can instantly produce export-grade biological products. To sell to western markets with strict regulations they have to prove their output still. They still need the high-end precision equipment to monitor, filter, and validate what's happening inside those tanks. Companies like Thermo Fisher (TMO) and Danaher (DHR) make the gold standard chromatography resins, membranes, and mass spectrometers the industry relies on. High regulatory switching costs mean a Chinese factory isn't going to risk failing an international audit by using a cheaper, unproven domestic filter. These enablers basically get to tax China's infrastructure build-out without ever having to compete on the price of the actual biological end-products.
* **Downstream Specialty Formulators** - meaning the companies that see margin expansion when inputs get cheap. If the global cost of raw bio-inputs crashes, the companies buying those materials win big. I'm looking at specialty chemical integrators like Croda (CRDA) or International Flavors & Fragrances (IFF). Since they sell proprietary patented formulations to global brands they can profit off the reduced input cost of the precursor bio-chemicals suddenly getting dirt cheap due to Chinese oversupply. Their value is protected by their brand relationships and western distribution networks, which Chinese commodity producers can't easily replicate.
* **Big Pharma Licensing Beneficiaries** - meaning Western giants acting as aggregators. There is a massive wave of novel biological assets being generated right now by state-funded Chinese labs. But these Chinese biotechs generally lack the global distribution networks to sell them worldwide. Western pharma giants like AstraZeneca (AZN) already have that network. They step in and buy the global rights to advanced, de-risked Chinese biological assets for pennies on the dollar compared to Western in-house R&D costs. They can let the Chinese state subsidize the early-stage discovery phases, scoop up the most promising assets, and push them through their own highly profitable Western sales channels. Part of this one is me assuming that trade barriers will remain in place to an extent, where China can't simply flood the market with copies of pharma giant products, and I don't foresee those trade barriers disappearing anytime soon.
Curious if anyone else is looking at this angle, or if you think the geopolitical risks (tariffs, IP theft) create a vulnerability on the hardware side of this? I'd also love to be proven wrong on the first 3 technology sectors having more of an effect than I'm anticipating. Currently I haven't invested in any of this, and am primarily doing research, and also do not work in BioTech so apologies if anything I said is completely out of touch.

DHR. It's one of those unique companies that never dies. Currently at $200.

Speaking from the past 5-year plans where solar, battery, transportation, R&D, urban development, etc. which inevitably sent ripples through the global economy in each of these sectors, I'd like to start a discussion on who we see profiting the most from China's 2026-2030 5 year plan.
The previous 5 year plan naturally resulted in many western companies floundering (for instance Germany used to produce solar panels) due to state sponsored Chinese industrial investments undercutting them. On the other hand, we have companies such as solar/battery installers and integrators that profited greatly from the new influx of cheap Chinese panels and batteries. But the previous 5 year plan is not where the long-term play is hiding, and I think the latest will be where we see new winners and losers arise.
The 4 main focus technology sectors in the latest 5 year plan that I see are:
* **"Embodied Intelligence"** - meaning humanoid robots, drones with industrial purpose, and AI with a physical presence
* **Further investment into green tech** - meaning green hydrogen equipment, next-gen solar, and advances in battery storage
* **6G, edge AI computing, optical components** - I see resulting in generally cheaper foundational networking components
* **SynBio and advanced biomanufacturing** - Cheaper bio-manufactured precursor chemicals and raw materials
I think a lot of profit can be made by determining not so much the next "big thing" or "bubble before it becomes a bubble," but instead looking at what the Chinese state is publicly telling us they are going to invest in, heavily, for 5 straight years and *who* will profit from the uptick in supply.
Now personally I believe the Embodied Intelligence space is overbought with the AI hype/bubble.
Green tech I believe already has these winners in place due to the previous 5 year plan and cheaper solar/energy storage. No doubt gains will continue to be made here, and perhaps there is something to consider for cheaper energy.
Cheaper networking components will likely make faster internet more affordable both for companies and consumers, however I don't see revolutionary changes likely in the ISP space.
This to me leaves the BioTech space where I think we will see businesses suddenly able to source significantly cheaper bio-manufactured precursor chemicals and raw materials. I could see western Biotech being undercut on design costs for commodity bio-chemicals by their Chinese subsidized equivalents, reverse engineered microbes being rapidly scaled, or Chinese self-reliance cutting out western hardware. On the other hand where I'm thinking the value might lie is with those best positioned to capitalize on China's building.
To me, there are three distinct buckets of companies poised to make a killing by benefiting from this incoming wave of Chinese biomanufacturing.
* **Precision Hardware & QA Enablers** - China is going to subsidize massive amounts of bioreactors and raw material platforms but that doesn't mean you they can instantly produce export-grade biological products. To sell to western markets with strict regulations they have to prove their output still. They still need the high-end precision equipment to monitor, filter, and validate what's happening inside those tanks. Companies like Thermo Fisher (TMO) and Danaher (DHR) make the gold standard chromatography resins, membranes, and mass spectrometers the industry relies on. High regulatory switching costs mean a Chinese factory isn't going to risk failing an international audit by using a cheaper, unproven domestic filter. These enablers basically get to tax China's infrastructure build-out without ever having to compete on the price of the actual biological end-products.
* **Downstream Specialty Formulators** - meaning the companies that see margin expansion when inputs get cheap. If the global cost of raw bio-inputs crashes, the companies buying those materials win big. I'm looking at specialty chemical integrators like Croda (CRDA) or International Flavors & Fragrances (IFF). Since they sell proprietary patented formulations to global brands they can profit off the reduced input cost of the precursor bio-chemicals suddenly getting dirt cheap due to Chinese oversupply. Their value is protected by their brand relationships and western distribution networks, which Chinese commodity producers can't easily replicate.
* **Big Pharma Licensing Beneficiaries** - meaning Western giants acting as aggregators. There is a massive wave of novel biological assets being generated right now by state-funded Chinese labs. But these Chinese biotechs generally lack the global distribution networks to sell them worldwide. Western pharma giants like AstraZeneca (AZN) already have that network. They step in and buy the global rights to advanced, de-risked Chinese biological assets for pennies on the dollar compared to Western in-house R&D costs. They can let the Chinese state subsidize the early-stage discovery phases, scoop up the most promising assets, and push them through their own highly profitable Western sales channels. Part of this one is me assuming that trade barriers will remain in place to an extent, where China can't simply flood the market with copies of pharma giant products, and I don't foresee those trade barriers disappearing anytime soon.
Curious if anyone else is looking at this angle, or if you think the geopolitical risks (tariffs, IP theft) create a vulnerability on the hardware side of this? I'd also love to be proven wrong on the first 3 technology sectors having more of an effect than I'm anticipating. Currently I haven't invested in any of this, and am primarily doing research, and also do not work in BioTech so apologies if anything I said is completely out of touch.

DHR. It's one of those unique companies that never dies. Currently at $200.